KRAS and squamous cell lung carcinoma: KRAS mutations are rarely detected in lung squamous cell carcinomas (LSCC) (between 4% to 8%), however, evaluation of the status in LSCC may be required in the near future, resulting in an increase in the workload and an increase in the budget dedicated to molecular biology testing, which should be taken into consideration [74,224].